LUP.F Luye Pharma Group Ltd
- Market cap
- EUR 726M
- P/E
- 17.9x
- P/B
- 0.36x
- ROE
- 3.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is LUP.F undervalued?
Graham numberLUP.F trades 46.3% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Luye Pharma Group Ltd fundamental analysis
No fundamental analysis for Luye Pharma Group Ltd yet.
Luye Pharma Group Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Luye Pharma Group Ltd
Luye Pharma Group Ltd., together with its subsidiaries, develops, produces, markets, and sells pharmaceutical products in the People's Republic of China, the United States, Europe, and internationally. The company offers Lipusu, for ovarian cancer and carcinoma of ovary; CMNa, a chemical sensitizer for cancer radiotherapy; Boyounuo, an injection for the treatment of various types of cancers; and Xuezhikang, a lipid-regulating drug for the treatment of hypercholesterolaemia. …
Full company profileLuye Pharma Group Ltd financial statements
Luye Pharma Group Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 2.92B | 3.81B | 5.17B | 6.36B | 5.54B | 5.20B | 5.98B | 6.14B | 6.06B | 6.31B |
| Gross Profit | 2.38B | 2.96B | 4.05B | 4.88B | 3.99B | 3.40B | 4.14B | 4.20B | 4.04B | 4.16B |
| Operating Income | 915M | 1.09B | 1.52B | 1.86B | 1.22B | 283M | 954M | 1.03B | 1.29B | 1.26B |
| EBITDA | - | 1.42B | 1.96B | 2.49B | 1.37B | 325M | 1.81B | 2.08B | 2.19B | 2.47B |
| Net Income | 892M | 981M | 1.30B | 1.47B | 707M | -134M | 605M | 533M | 472M | 619M |
| EPS | - | 0.31 | 0.40 | 0.47 | 0.23 | -0.04 | 0.18 | 0.14 | 0.13 | 0.15 |
| Balance Sheet | ||||||||||
| Total Assets | 9.21B | 10.8B | 17.5B | 19.3B | 20.6B | 22.6B | 24.2B | 25.5B | 29.6B | 32.8B |
| Total Liabilities | 2.64B | 3.86B | 9.60B | 9.94B | 12.5B | 13.5B | 13.2B | 12.0B | 13.9B | 14.5B |
| Shareholders' Equity | 6.43B | 6.77B | 7.81B | 9.22B | 7.89B | 8.49B | 10.2B | 12.5B | 14.2B | 16.1B |
| Cash & Short-term Investments | 398M | 1.27B | 1.67B | 2.33B | 3.87B | 2.44B | 2.32B | 5.65B | 4.94B | 4.49B |
| Cash Flow | ||||||||||
| Operating Cash Flow | 592M | 964M | 1.05B | 1.42B | 1.03B | 182M | 1.65B | 1.60B | 168M | 1.78B |
| Capital Expenditure | 319M | 507M | 728M | 999M | 693M | 556M | 1.16B | 1.17B | 1.71B | 1.00B |
| Free Cash Flow | - | 339M | -1.44B | -1.48B | -486M | -1.36B | 490M | 430M | -1.54B | 780M |
| Ratios | ||||||||||
| ROE | 13.9% | 14.5% | 16.7% | 15.9% | 9.0% | -1.6% | 5.9% | 4.3% | 3.3% | 3.8% |
| ROA | 9.7% | 9.1% | 7.4% | 7.6% | 3.4% | -0.6% | 2.5% | 2.1% | 1.6% | 1.9% |
| Net Profit Margin | 30.6% | 25.7% | 25.2% | 23.1% | 12.8% | -2.6% | 10.1% | 8.7% | 7.8% | 9.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Luye Pharma Group Ltd dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jun 29, 2020
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | CNY 175M | 0.06 | 24.8% |
| 2019 | EUR 377M | 0.12 | 25.7% |
| 2018 | EUR 290M | 0.09 | 22.2% |
| 2017 | EUR 213M | 0.07 | 21.7% |
| 2016 | EUR 107M | - | 12.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Luye Pharma Group Ltd
- Insiders 31.20%
- Institutions 28.43%
- Public & others 40.38%
- Shares outstanding 3.99B
- Free float 2.20B
Luye Pharma Group Ltd company profile
- Company name
- Luye Pharma Group Ltd
- Ticker
- LUP.F
- ISIN
- BMG570071099
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 5,270
- Fiscal year end
- December
- Address
- No. 15 Chuang Ye Road, Yantai, China, 264003
- Website
- luye.cn
About Luye Pharma Group Ltd
Luye Pharma Group Ltd., together with its subsidiaries, develops, produces, markets, and sells pharmaceutical products in the People's Republic of China, the United States, Europe, and internationally. The company offers Lipusu, for ovarian cancer and carcinoma of ovary; CMNa, a chemical sensitizer for cancer radiotherapy; Boyounuo, an injection for the treatment of various types of cancers; and Xuezhikang, a lipid-regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema and edema caused by trauma or surgery, and for treatment of venous reflux disorders; Beixi, an acarbose capsule for Type 2 diabetes mellitus; Seroquel, Seroquel XR, Erzofri; and Rivastigmine Multi-Day Transdermal, Rotigotine transdermal, Fentanyl, and Buprenorphine patches. In addition, the company offers Rykindo, an injection for the treatment of schizophrenia; Boyoubei, a denosumab injection for the treatment of postmenopausal women with osteoporosis; and Boyouping, a dulaglutide injection for glycemic control in adults. Further, it offers Oukai; Meibirui; Jinyouping; and other products. The company distributes and sells pharmaceutical drugs; develops, manufactures, and commercialises of biologics; and manufactures and sells biopharmaceutical products. Luye Pharma Group Ltd. was founded in 1994 and is headquartered in Yantai, the People's Republic of China.
Luye Pharma Group Ltd management
6- Mr. Dian Bo LiuCo-Founder, Executive Chairman, CEO and Head of Corporate Directions & Strategies · born 1966
- Mr. Rong Bing YangCo-Founder & Vice Executive Chairman · born 1966
- Mr. Hui Xian YuanCo-Founder & Executive Director · born 1959
- Ms. Yuan Yuan ZhuExecutive Director · born 1981
- Mr. Yuan Chong LiuChief Financial Officer · born 1964
- Ms. Mei Yi Lee ACIS, ACS, FCIS, FCSCompany Secretary · born 1968